COMMUNIQUÉS West-GlobeNewswire

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
23/01/2025
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will [...]
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
23/01/2025
News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro [...]
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
23/01/2025
Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading [...]
STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
22/01/2025
DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9: [...]
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
22/01/2025
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
22/01/2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Bionano Announces Effective Date of Reverse Stock Split
22/01/2025
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for [...]
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
22/01/2025
Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO [...]
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
22/01/2025
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Nusano to Present at Piper Sandler Next-Gen RadioPharma Symposium
22/01/2025
VALENCIA, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at Piper Sandler’s Next-Gen [...]
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
22/01/2025
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the [...]
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
22/01/2025
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025
22/01/2025
Daix (France), New York City (New York, United States), le 22 janvier 2025 – Inventiva (Euronext Paris and Nasdaq :IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/01/2025
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of [...]
AB Science will participate in the Biomed Forum investors conference
22/01/2025
PRESS RELEASE AB SCIENCE WILL PARTICIPATE IN THE BIOMED FORUM INVESTORS CONFERENCE Paris, 22 january 2024, 7pm CET AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the [...]
AB Science participera à la conférence investisseurs Biomed Forum
22/01/2025
COMMUNIQUE DE PRESSE AB SCIENCE PARTICIPERA À LA CONFÉRENCE INVESTISSEURS BIOMED FORUM Paris, 22 janvier 2024, 19h AB Science SA (Euronext – FR0010557264 – AB) annonce aujourd'hui la participation de son équipe de [...]
Spineway : 2024 revenue of €12 million - 14% growth compared with 2023
22/01/2025
Press release Ecully, January 22, 2025 – 6.30 p.m. SPINEWAY 2024 revenue of €12 million 14% growth compared with 2023 In thousands of euros 2024 2023 Change as a % H1 revenue 6,535 5,431 +20% H2 revenue 5,415 5,088 +6% [...]
Spineway : Chiffre d’affaires annuel 2024 de 12 M€ - Croissance de 14% par rapport à 2023
22/01/2025
Communiqué de presse Ecully, le 22 janvier 2025 –18h30 SPINEWAY Chiffre d’affaires annuel 2024 de 12 M€ Croissance de 14% par rapport à 2023 En milliers d’euros 2024 2023 Variation en % CA 1 er semestre 6 535 5 431 + 20 [...]
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
22/01/2025
Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose [...]

Pages